The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Gene identification
研究概览
简要总结
The objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.
详细描述
It is estimated that over one-third of the world's population suffers from persistent or recurrent pain. Migraine is highly heritable and the majority of juveniles who suffer from the disorder have a mother or father who also have the disease. The blood or saliva samples will go through DNA analysis and be sequenced for candidate genes or subjected to whole-genome sequencing. By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.
研究设计
- 研究类型
- Observational
- 观察模型
- Family Based
入排标准
- 年龄范围
- 10 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial
- •Adolescent and at least 1 biologic parent with Migraine diagnosis confirmed by Dr. Christy Jackson
- •Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented
- •Able to understand and grant informed consent
排除标准
- •Patient has been previously enrolled in the MAP GeneBank at Scripps Clinic Registry
- •Has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study
- •Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
- •Has undergone ECT within 90 days preceding enrollment in the study
结局指标
主要结局
Gene identification
时间窗: end of study
By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.
次要结局
未报告次要终点
研究者
Eric Topol, MD
Director, Scripps Translational Science Institute
Scripps Translational Science Institute